<DOC>
	<DOCNO>NCT02859766</DOCNO>
	<brief_summary>This study evaluate safety characterize systemic pharmacokinetics ( PK ) free vascular endothelial growth factor ( VEGF ) -bound abicipar follow single multiple intravitreal injection abicipar pegol treatment-na√Øve patient neovascular age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Safety Pharmacokinetics Abicipar Pegol Intravitreal Injections Patients With Neovascular AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Presence active subfoveal and/or juxtafoveal choroidal neovascularization ( CNV ) secondary agerelated macular degeneration ( AMD ) . History active periocular , ocular , intraocular infection . Previous use verteporfin photodynamic therapy ( PDT ) ocular antiangiogenic therapy ( eg , aflibercept , bevacizumab , ranibizumab , pegaptanib ) , approve investigational , treatment neovascular AMD previous therapeutic radiation region . Prior use ocular antiVEGF agent neovascular eye disease AMD . Macular hemorrhage involve center fovea study eye . Any prior current systemic ocular treatment ( include surgery ) neovascular AMD study eye . Treatment ocular corticosteroid injection implant within 6 month study eye . History evidence eye surgery : Pars plana vitrectomy , Submacular surgery surgical intervention AMD , Incisional glaucoma surgery Cataract refractive surgery within last 3 month . AMD nonstudy eye require antiVEGF treatment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>